LSM with a known etiology shows better therapeutic outcomes, as riboflavin-responsive MADD (RR-MADD) with ETFDH mutation and carnitine-responsive PCD with SLC22A5 mutation. The gene discussed is ETFDH; the disease is multiple acyl-CoA dehydrogenase deficiency.